RECOVER-TLC invites public comments on upcoming clinical trials
Patients, caregivers, advocates, healthcare providers, and researchers can sign up to provide feedback on RECOVER-TLC’s plans to study potential Long COVID treatments.
RECOVER-Treating Long COVID (RECOVER-TLC) invites members of the public to provide feedback on draft protocol synopses for its upcoming clinical trials. Draft protocol synopses are summaries of proposed study plans. These summaries use plain language to explain the questions the study will investigate, how researchers will look for answers, and who can join the study.
RECOVER-TLC clinical trials will test the safety and effectiveness of different treatments, like medicines and medical devices, for specific symptoms of Long COVID. Public feedback will help ensure that these trials set achievable goals, are accessible to people affected by Long COVID, and produce meaningful results.
Anyone wishing to review draft protocol synopses and submit feedback must register to become a public commenter through the RECOVER-TLC Collaborator Portal. Registered public commenters will receive email notifications as draft protocols become available.
Comments on the draft protocol synopsis for the RECOVER-TLC Low-dose Naltrexone (LDN) clinical trial will be accepted from November 24, 2025, through December 9, 2025. The purpose of this trial will be to test whether LDN is an appropriate treatment for children and young adults who experience exhaustion or low energy (fatigue) due to Long COVID.
For help with any issues registering through the RECOVER-TLC Collaborator Portal, please email recover-tlc@rti.org.
Visit the Foundation for the NIH (FNIH) website to learn more about RECOVER-TLC, how information about potential Long COVID treatments is collected, and how treatments are selected for testing in clinical trials.